Skip to main content

Breakthroughs in Drug development

World’s fastest AI-discovered medicine enters phase 2a trial, marking breakthroughs in drug development


Researchers from Peking Union Medical College Hospital and artificial intelligence (AI) drug developer Insilico Medicine published phase 2a clinical trial data for a small-molecule treatment for idiopathic pulmonary fibrosis (IPF) in Nature Medicine magazine on Tuesday. Data demonstrates preliminary safety and efficacy of the drug candidate, making it the fastest-progressing AI-discovered drug worldwide to date, according to a report by The Paper.

IPF is a chronic, progressive lung disease characterized by irreversible decline in lung function, affecting an estimated 5 million people worldwide. The median survival is only three to four years. Existing treatments can slow the disease's progression but cannot halt or reverse it, according to The Paper. The molecule tested in this trial, Rentosertib, targets TNIK - a novel site identified with the help of AI, as research group say in the Nature Medicine.

In the development of new drugs, a "target" is like a lock that a drug - the key- must fit. Traditionally, identifying the correct target is time-consuming and depends heavily on trials and errors. In the case of Rentosertib, AI helped researchers pinpoint a previously overlooked target, significantly enhancing discovery efficiency, Chen Jing, a vice president of the Technology and Strategy Research Institute, told the Global Times on Wednesday.

"AI has already made major breakthroughs in drug-related fields," Chen said. "Its success in identifying a novel target represents a natural extension of that capability into basic research. The core competency is present - with ongoing data accumulation and training, large-scale application and major results are only a matter of time."

While AI has long been expected to accelerate drug development by efficiently screening compounds, simulating mechanisms and supporting clinical trial design, no AI-discovered drugs had advanced beyond phase 1 trials until now. Rentosertib's progression into phase 2a marks a significant milestone, demonstrating AI's tangible impact on real-world pharmaceutical innovation, per the report.

Clinical observations showed that Rentosertib had demonstrated manageable safety and tolerability, laying the groundwork for larger and longer-term trials. The experience with Rentosertib highlights the transformative potential of AI in drug development and offers a valuable reference for more efficient and innovative approaches, said Dr. Alex Zhavoronkov, founder and CEO of Insilico Medicine, the report noted.

"AI is making steady progress in fields such as medical imaging, clinical decision support, and personalized health monitoring," Chen said. "But in drug development, it still faces major challenges — from limited access to high-quality data and poor model interpretability to high computational costs and a shortage of interdisciplinary talent. Intellectual property and regulatory frameworks also need to evolve. If these issues are properly addressed, AI has the potential to truly advance inclusive and accessible healthcare forward."

AI applications in China's healthcare sector are expected to expand in scale and diversify across more use cases in the future, expert said. China's medical AI market is projected to reach $13.4 billion by 2026, with an annual growth rate exceeding 40 percent, according to an IDC report, quoted by the Xinhua News Agency.

Comments

Post a Comment

Popular posts from this blog

Fruitful innovation

Fruitful innovation: Transforming watermelon genetics with advanced base editors The development of new adenine base editors (ABE) and adenine-to-thymine/ guanine base editors (AKBE) is transforming watermelon genetic engineering. These innovative tools enable precise A:T-to-G and A:T-to-T base substitutions, allowing for targeted genetic modifications. The research highlights the efficiency of these editors in generating specific mutations, such as a flowerless phenotype in ClFT (Y84H) mutant plants. This advancement not only enhances the understanding of gene function but also significantly improves molecular breeding, paving the way for more efficient watermelon crop improvement. Traditional breeding methods for watermelon often face challenges in achieving desired genetic traits efficiently and accurately. While CRISPR/Cas9 has provided a powerful tool for genome editing, its precision and scope are sometimes limited. These limitations highlight the need for more advanced gene-e...
Post a Comment
Read more

Genetic factors with clinical trial stoppage

Genetic factors associated with reasons for clinical trial stoppage Many drug discovery projects are started but few progress fully through clinical trials to approval. Previous work has shown that human genetics support for the therapeutic hypothesis increases the chance of trial progression. Here, we applied natural language processing to classify the free-text reasons for 28,561 clinical trials that stopped before their endpoints were met. We then evaluated these classes in light of the underlying evidence for the therapeutic hypothesis and target properties. We found that trials are more likely to stop because of a lack of efficacy in the absence of strong genetic evidence from human populations or genetically modified animal models. Furthermore, certain trials are more likely to stop for safety reasons if the drug target gene is highly constrained in human populations and if the gene is broadly expressed across tissues. These results support the growing use of human genetics to ...
Post a Comment
Read more

Genetic Test

Genetic test eliminates progressive retinal atrophy in English shepherd dogs Researchers at the University of Cambridge recently published their findings in Genes after identifying the genetic mutation that is causing progressive retinal atrophy (PRA) in English shepherd dogs. PRA is a group of inherited diseases causing progressive degeneration of the light sensitive cells within the back of the eyes. When it comes to PRA in dogs, they are born with normal vision but by the age of 4-5 they go totally blind with no treatment. According to the release, by identifying the canines carrying this disease before they lose vision, this can be then used as a tool to guide breeding decisions to prevent the passing of the disease onto puppies.1 Historically, owners did not realize their dog had PRA until they were middle-aged, which means it could have been passed on to puppies if they had bred, making this a hard disease to control. “Once the dog’s eyesight starts to fail there’s no treatment ...
Post a Comment
Read more